Pfizer to Launch Multiple Unapproved Vaccines and Oncology Drugs in China's Boao Lecheng Medical Tourism Pilot Zone

Pfizer Biopharmaceuticals Group and the Hainan Boao Lecheng International Medical Tourism Pilot Zone signed a cooperation agreement at the Second China International Import Expo.

Multiple drugs, including the adult indications for Pfizer’s pneumococcal polysaccharide conjugate vaccine approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), meningococcal ACWY conjugate vaccine, serogroup B meningococcal vaccine, the novel antifungal drug Kangxinbo, lorlatinib for non-small cell lung cancer, and inotuzumab ozogamicin, an antibody-drug conjugate for acute lymphoblastic leukemia, will be launched in the Boao Lecheng International Medical Tourism Pilot Zone.